The combination of Astragalus membranaceus extract and ligustrazine to improve the inflammation in rats with thrombolytic cerebral ischemia

Ruihuan Pan1*, Mingchao Zhou2*, Yiping Zhong3, Jingping Xie4, Shanshan Ling1,3, Xialin Tang3, Yan Huang5 and Hongxia Chen1

Abstract
The purpose of the study was to evaluate the effect of Astragalus membranaceus extract and ligustrazine combination on ameliorating inflammation in cerebral ischemic rats that have undergone thrombolysis. Astragalus membranaceus and ligustrazine per se, or a combination of A. membranaceus and ligustrazine was administered by intraperitoneal injection immediately after surgery and sham surgery. After the induction of thrombolysis, the neurological function was measured and cerebral lesion volume was determined. The regulatory T cells in the spleen were measured by flow cytometry. To explore the protective effects of the combination drug on the neurological function and inflammation, the expression of transcription factor Foxp3 and cytokines, including transforming growth factor beta 1, interleukin 10, interleukin 4, interleukin 1 beta, interferon gamma, interleukin 17, in damaged brain was examined using reverse transcription polymerase chain reaction, Western blot, and enzyme-linked immunosorbent assay. The cerebral lesion volume was markedly reduced in the combination drug–treated rats compared to the rats treated with either A. membranaceus or ligustrazine alone (P < 0.05). The neurological function, regulatory T cells, transcription factor Foxp3, transforming growth factor beta 1, interleukin 10, and interleukin 4 were markedly elevated in the rats treated with combination drugs (P < 0.05). The expression of interleukin 1 beta, interferon gamma, and interleukin 17 was reduced in the rats treated with combination drug therapy (P < 0.05). Treatment with a combination of A. membranaceus and ligustrazine can ameliorate inflammation after thrombolysis and regulate the related cytokines by elevating the expression of endogenous regulatory T cells.

Keywords
Astragalus membranaceus, endogenous regulatory T cells, inflammation, ligustrazine, thrombolysis

Date received: 21 May 2019; accepted: 19 July 2019

1Department of Rehabilitation, The 2nd Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China
2Department of Rehabilitation, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
3The Second Institute of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China
4School of Biomedical Sciences and KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research of Common Diseases, The Chinese University of Hong Kong, Sha Tin, Hong Kong
5Diagnosis and Treatment Center of Encephalopathy, The 2nd Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China

* Ruihuan Pan and Mingchao Zhou contributed to this work equally.

Corresponding authors:
Yan Huang, Diagnosis and Treatment Center of Encephalopathy, The 2nd Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
Email: gdszyhy@163.com
Hongxia Chen, Department of Rehabilitation, The 2nd Affiliated Hospital, Guangzhou University of Chinese Medicine, No. 111, Dade Road, Yuexiu District, Guangzhou 510000, Guangdong, China.
Email: chx2004@foxmail.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the gold standard treatment for acute cerebral stroke within the first 4.5 h. However, the treatment can lead to ischemia-reperfusion injury (R/I), which includes the blood–brain barrier (BBB) destruction, cerebral edema, and hemorrhagic transformation (HT). The mechanisms of ischemia-R/I are complex, which include excitatory amino acids toxicity, calcium overload, inflammatory reaction, oxidative damage, and apoptosis. Among the above-mentioned mechanisms, inflammation is a major contributing factor of R/I. Recent studies showed that regulatory T cells (Tregs) play an important role in reducing inflammation, mitigating the permeability of BBB, and decreasing the cerebral lesion volume in the treatment of R/I after acute ischemic stroke. The therapy that combines Tregs with rt-PA can ameliorate inflammation after reperfusion treatment in stroke rats model. Hence, Tregs can be a promising treatment for ischemia-R/I.

In Chinese medicine, the main pathology of R/I after thrombolysis is qi deficiency and blood stasis. Therefore, the main treatment focuses on synergizing qi and promoting blood circulation, which can be obtained by administering the widely used Chinese medicines Astragalus membranaceus and ligustrazine. A. membranaceus is known to invigorate qi, is also known as an anti-oxidant, and provides neuroprotection. On the contrary, ligustrazine has blood circulation properties that help regulation and has anti-oxidant, anti-apoptotic, and anti-inflammatory properties. Clinical study had revealed that Buyang Huanwu decoction combined with tPA can improve the neurological function and preserve BBB integrity in acute stroke mice. A. membranaceus and ligustrazine are the main compounds of Buyang Huanwu decoction. Our previous study had found that A. membranaceus and ligustrazine combination can improve the tight junctions of BBB in middle cerebral artery occlusion (MCAO) rats. However, it is still unclear whether the regulatory T cells are involved in the protective mechanisms of the combinative treatment. Therefore, the objective of this study is to evaluate the effect of A. membranaceus and ligustrazine combination on ameliorating inflammation reaction in cerebral ischemic rats that have undergone thrombolysis, based on the endogenous Treg cells and related cytokines profiles.

Methods

Animals

The animal experiments were performed according to the procedures formulated by the Institutional Animal Care and Use Committee (IACUC) of Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China. This procedure was in accordance with the guidelines of European Community (EEC Directive in 1986; 86/609/EEC). Adult male Wistar rats (provided by Medical Laboratory Animal Center of Guangdong, Guangzhou, China) weighing 250–300 g and aged 3–4 months were maintained in the animal room (SPF, Animal Experimental Center, Guangdong Academy of Chinese Medicine, Guangzhou, China) at 22 ± 2°C and 55 ± 2% relative humidity on a 12-h light/dark cycle with free access to food and water.

According to Overgaard et al. and Zhang et al., the autologous embolus was prepared as follows: first, 20 μL of blood was withdrawn from the femoral artery and injected into a 20-cm PE-50 tube. Second, 1U thrombin was injected into the PE-50 tube. After 15 min, a 30- to 35-mm (1.0 μL) autologous clot was formed. Third, the clot was withdrawn into a Hamilton syringe. Finally, an embolus with 0.5 cm of length was ready for injection.

The MCAO models were made as follows: first, the animals were anesthetized with 0.35 mL/100 g 10% Chloral Hydrate by intraperitoneal injection. Second, the rat model was set in a supine position, followed by the sanitation of the skin. Afterward, an incision was made in the middle of the neck under an operating microscope. Third, the right common carotid artery (CCA), internal carotid artery (ICA), and external carotid artery (ECA) were exposed by blunt dissection. Fourth, a 15-mm long autologous embolus was carefully injected in a rapid manner into the ICA lumen. In the end, the skin was sutured to close the wound and the model was completed. The sham surgery was conducted in similar manner as the method described above, but without the injection of autologous embolus.

Experimental design

The animals were randomly divided into six groups, namely, sham (n=72), MCAO (n=72), thrombolysis (n=72), Astragalus (n=72), Ligustrazine (n=72),...
and Ast + Lig groups (n=72). The A. membranaceus for injection (10 mL/piece, the astragaloside content was 10 mg/mL) was ordered from the Chiatai Qingchunbao Pharmaceutical Company (Hangzhou, China; Batch: 1112043), and the ligustrazine for injection (10 mL/piece, the tetramethylpyrazine content was 10 mg/mL) was purchased from Zhengzhou Cheuk-Fung Pharmaceutical Company (Zhengzhou, China; Batch: 11101312). The chemical structure of ligustrazine and the official chromatography fingerprints of A. membranaceus are shown in Figure 1.

Figure 1. (a) The chemical structure of ligustrazine and (b) the experimental design. The pharmaceuticals were intraperitoneally injected immediately after ischemic stroke. rt-PA was intravenously injected for thrombolysis 3 h after ischemic stroke. Neurological assessment and TTC staining were conducted at 3, 6, and 24 h after thrombolysis induction. ELISA, qRT-PCR, and Western blot assays were conducted at 3 and 24 h after thrombolysis induction.

rt-PA: recombinant tissue plasminogen activator; qRT-PCR: quantitative reverse transcription polymerase chain reaction; TTC: triphenyl tetrazolium chloride; ELISA: enzyme-linked immunosorbent assay.

According to previous studies, saline was added into the A. membranaceus (2 mL/kg) and ligustrazine (1 mL/kg) to prepare 3 mL solutions for injection. Immediately after ischemic stroke, animals in different groups were intraperitoneally injected with saline (3 mL, sham group and MCAO group), A. membranaceus (2 mL/kg, Astragalus group), ligustrazine (1 mL/kg, Ligustrazine group), or A. membranaceus (2 mL/kg) and ligustrazine (1 mL/kg, 3 mL final volume, Ast + Lig group) combination. At 3 h after ischemic stroke, all animals except those in sham and MCAO groups were intraperitoneally injected with rt-PA (5 mg/kg, Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany) for thrombolysis. Neurological assessments and triphenyl tetrazolium chloride (TTC) staining assay were performed on the rats from all groups (n=6 at each time point) at 3 and 24 h after thrombolysis. The experimental design is shown in Figure 2.

Neurological assessment

We measure the neurological function of the rats at 3, 6, and 24 h after the induction of cerebral ischemia according to modified Bederson’s examination system as previously reported.15 There are five levels of the neurologic examination grading system in which the scores are as follows: 0 indicates no obvious neurological deficit, 1 indicates disabled forelimb flexion, 2 indicates decreased resistance of disabled forelimb when pulling tail, 3 indicates moving to all directions spontaneously but circling to the disabled side when pulling tail, and 4 indicates circling to the disabled side spontaneously.

TTC staining

The TTC staining to measure the ischemic volumes was conducted as follows: (1) the brains from models were sliced into 2-mm slices using a rat-brain matrix (RWD, Life Science); (2) the sample slice was incubated at 37°C for 20 min in 2% 2, 3, 5-TTC solution (Sigma-Aldrich); (3) the sample sections were photographed and analyzed by a double-blind collaborator using the ImageJ software (NIH Program, Bethesda, MD, USA); and (4) as according to previous studies,16 the ischemic
volumes were calculated by summing the thicknesses of the brain slices multiplied by the infarction areas across different brain slices.

**ELISA analysis**

The levels of transforming growth factor beta 1 (TGF-β1), interleukin-10 (IL-10), interferon gamma (IFN-γ), and IL-17 in serum were assessed using ELISA kit. The peripheral blood was collected and centrifuged at 3000 r/min to prepare the serum. Further, the serums were processed according to the manufacturer’s instructions of the ELISA kit. At last, the prepared serums were assayed using a microplate reader (BIO-RAD, America). Each serum sample was tested three times to get the mean value.

**Quantitative real-time PCR**

The expression levels of Foxp3, TGF-β1, IL-10, IL-4, IL-1β, IFN-γ, and IL-17 mRNA were assessed using TaqMan real-time PCR. The total RNA of the brain samples was isolated using Trizol reagents (Invitrogen). cDNA for the amplified templates was synthesized from the total RNA by means of a PrimeScript RT reagent kit (TaKaRa Bio; Shiga, Japan). The primers designed using the Premier 5.0 biological software and synthesized by Sangon Biotechnology Company (Shanghai, China) are shown in Table 1. RT-PCR was performed in a model 7300 sequence detector (PE Applied Biosystems; Chiba, Japan) using an SYBR Premix EX Taq II Kit (TaKaRa Bio; Shiga, Japan). The experiments were repeated twice.

**Western blot analysis**

The brain samples were lysed in high-efficiency RIPA (radioimmunoprecipitation assay) lysate that contains 20 mmol/L Tris (pH 7.6), 0.2% SDS (sodium dodecyl sulfate), 1% deoxycholate, 1% Triton X-100, 0.11 IU (international units)/mL.
aprotinin, and 1 mmol/L phenylmethylsulphonyl fluoride (all purchased from Sigma-Aldrich). The protein samples, 5 µg each lane, were subjected to 8% SDS-PAGE (sodium dodecyl sulfate–polyacrylamide gel electrophoresis) and subjected to electrophoresis at 120 V. Subsequently, the isolated proteins were transferred to PDNF (parasite-derived neurotrophic factor) membrane in 300 mA. The following antibodies were used: Foxp3 (1:1000 dilution; Millipore), TGF-β1 (1:500 dilution; Abcam), IL-10 (1:1000 dilution; Abcam), and β-actin (1:6000 dilution; Sigma-Aldrich). The Western blots were quantified with ImageJ software (NIH Program, Bethesda, MD, USA). The experiments were conducted three times.

Flow cytometry

To prepare spleen cell suspensions, excised spleen with the size of 8 × 4 mm were cut, grind, and sieved into single-cell suspensions. After repeated suspending and washing, the cells were surface stained with fluorescein isothiocyanate (FITC)-labeled antibodies against rat CD4 together with allophycocyanin-labeled antibodies against rat CD25 at room temperature for 45 min. Then, the cells were washed, fixed, permeabilized with buffer (Cytofix/Cytoperm; eBioscience), and intracellularly stained with phycoerythrin (PE)-labeled antibodies against Foxp3 (eBioscience). The samples were examined using a flow cytometer (ACEA NovoCyte TM D2060R, ACEA Biosciences, USA) and analyzed using a software (CellQuest, Becton Dickinson, USA).

Statistical analyses

The data are presented as the means ± the standard deviation. The multiple-group comparisons were performed by one-way analyses of variance (ANOVAs) followed by Student–Newman–Keuls’ or Dunnett’s post hoc tests. The internal-group comparisons were performed by T tests. The bars in the icon indicate the means ± the SEMs. The statistical analyses were conducted with SPSS software (21.0, Chicago, IL, USA). A P-value < 0.05 was considered significant.

Result

The infarct volumes of each group

The result of TTC staining shows that the ischemic volumes in the MCAO, thrombolysis, ligustrazine, Astragalus, and Ast + Lig groups were 285.23 ± 25.32 mm³, 264.85 ± 33.43 mm³, 243.22 ± 22.56 mm³, 247.37 ± 23.56 mm³, and 215.73 ± 17.85 mm³. The result indicates that the focal cerebral infarctions had been successfully implanted in the animals (representative examples are shown in Figure 2). Furthermore, the combination therapy can decrease the infarct volumes in cerebral ischemic rats. There were no ischemic areas in the sham group.

Neurological assessment

To determine the neuroprotective effect of the combination therapy, we examined the neurological function for each group at 3, 6, and 24 h after thrombolysis, as shown in Figure 3. Observation at 3 and 6 h after thrombolysis showed no significant difference in neurological function between sham group (0,0), thrombolysis group (3.33 ± 0.52, 3.50 ± 0.55), MCAO group (3.45 ± 0.57, 3.56 ± 0.63), Astragalus group (3.17 ± 0.61, 3.17 ± 0.41), Ligustrazine group (3.17 ± 0.61, 3.00 ± 0.63), and Ast + Lig group (3.00 ± 0.85, 2.85 ± 0.40, P > 0.05). After 24 h of thrombolysis,
the neurological function was significantly reduced in the Ast + Lig group (2.67 ± 0.52) compared to the thrombolysis group (3.33 ± 0.52) and MCAO group (3.47 ± 0.52, *P* < 0.05). However, there were no significant differences between Ast + Lig group, Astragalus group, and Ligustrazine group (*P* > 0.05). The results are shown in Figure 3.

**Combination drug treatment ameliorated inflammation response after thrombolysis**

To explore the effect on ameliorating inflammatory response of the combination therapy, we examined the cytokine for each group at 3 and 24 h after thrombolysis, as shown in Figures 5–7. There were no significant differences in TGF-β1, IL-10, IL-4, IL-1β, IFN-γ, and IL-17 between groups (*P* > 0.05) at 3 h after thrombolysis. The gene expression of TGF-β1, IL-10, IL-4 increased significantly after 24 h of thrombolysis in the Ast + Lig group compared to any other groups (*P* < 0.05). The levels of IL-1β, IFN-γ, and IL-17 in serum were significantly reduced in the Ast + Lig group compared to other groups (*P* < 0.05).

These results proved that the *A. membranaceus* and ligustrazine combination therapy has the effect of ameliorating inflammation response after thrombolysis by upregulating the anti-inflammatory cytokines and reducing the pro-inflammatory cytokines.

**Combination drug treatment upregulated Treg cells level in spleen after thrombolysis**

To explore the effect on Treg cells of the combination therapy, we examined the Tregs level in the spleen for each group at 3 and 24 h after thrombolysis, as shown in Figure 8. The flow cytometry results showed that there was no significant difference in Tregs level between sham groups (*P* > 0.05) at 3 h after thrombolysis. The Tregs level in the spleen increased significantly in the Ast + Lig group compared to sham group, thrombolysis group, and MCAO group (*P* < 0.05) after 24 h of thrombolysis.

**Discussion**

R/I treatment with rt-PA in acute ischemic stroke patients can induce inflammation reaction which may result in the increased risk of BBB damage and hemorrhage transformation. In order to obtain safer application of rt-PA treatment, it is necessary to explore effective therapies to decrease these complications. Recent studies had proved...
Figure 4. Gene expression assay of Foxp3, TGF-β1, IL-10, IL-4, IL-1β, INF-γ, IL-17 by RT-PCR. The histograms indicate the (a) Foxp3 gene expressions, (b) TGF-β1 gene expressions, (c) IL-10 gene expressions, (d) IL-4 gene expressions, (e) IL-1β gene expressions, (f) INF-γ gene expressions, (g) IL-17 gene expressions in the sham, MCAO, thrombolysis, Astragalus, Ligustrazine, Ast + Lig groups (n = 6 at each time point).

RT-PCR: reverse transcription polymerase chain reaction; MCAO: middle cerebral artery occlusion.

*P < 0.05, compared with sham group.
that endogenous Tregs could protect against ischemic brain injury.\textsuperscript{17} In addition, the administration of Tregs together with rt-PA thrombolysis could reduce cerebral hemorrhages in ischemic stroke animals. Tregs also have neuroprotective effect and alleviating BBB damage in models of cerebral R/I.\textsuperscript{18} Therefore, upregulating endogenous Tregs would be a promising method for the treatment of R/I.

Previous studies have found that \textit{A. membranaceus} and ligustrazine can protect BBB in cerebral stroke.\textsuperscript{19,20} Our previous studies have also confirmed that \textit{A. membranaceus} and ligustazine combination could protect the BBB integrity after rt-PA thrombolysis treatment in cerebral ischemic rats.\textsuperscript{12} Since the BBB damage is mainly caused by inflammation reaction after R/I treatment, it can lead to secondary damage of the neurological function.\textsuperscript{21} Therefore, we speculated that the combination therapy may provide anti-inflammation property that induces potentially protective effect to the neurological function.
As shown by the results, the rt-PA thrombolysis treatment may not obviously improve neurological function effectively within 24 h of intervention. The rt-PA thrombolysis treatment supplemented with *A. membranaceus* or ligustrazine can ameliorate neurological function at 6 and 24 h after intervention, but the effects were limited. Only the combination therapy of rt-PA, *A. membranaceus*, and ligustrazine showed a significant effect at 24 h after intervention. The effects were better than any other groups with single compound intervention. This phenomenon can reflect the additive effect of the two substances. In pharmacological studies, *A. membranaceus* provides anti-inflammatory, immunostimulation, and anti-oxidative properties. On the contrary, Ligustrazine provides anti-inflammatory, anti-oxidative, and neuroprotective properties. The combination of both substances has
been used in many traditional Chinese medicines, especially the Buyang Huanwu decoction, which facilitates neurorehabilitation. Our findings revealed that the combination therapy strengthened the neuroprotective effects.

Next, we explored the correlation of the neuroprotective effects of the combination therapy with its anti-inflammation property. In the inflammatory-related cells and cytokines assay, pro-inflammatory cytokines IL-17, IFN-γ and IL-1β in the damaged brain clearly increased after rt-PA thrombolysis treatment. At the same time, the Tregs in the spleen and the related cytokines (TGF-β, IL-10) were markedly decreased. However, after the intervention of Ast + Lig combination therapy, Tregs and its related cytokines (TGF-β, IL-10) were significantly increased, meanwhile the IL-17, IFN-γ, and IL-1β significantly decreased. This combination therapy also increased the expression of Foxp3, the main transcription factor of Tregs, and maintained the Tregs immune tolerance function. These results are similar to the study of Arthur et al., who had found that the expression levels of pro-inflammatory cytokines tumor necrosis factor alpha (TNF-α), IL-1β and IFN-γ were reduced after Tregs depletion in the ischemic brain. Therefore, we could infer that the A. membranaceus and ligustrazine combination provides neuroprotection and anti-inflammation effects after cerebral R/I for stroke rats.

The neuroprotective and anti-inflammatory effect mechanism of the combination therapy lies in two aspects. On one hand, previous study has proved that Tregs can protect rt-PA-mediated BBB damage in stroke mice. Our previous study also found that the A. membranaceus and ligustrazin combination therapy can maintain the integrity of the BBB. Therefore, the neuroprotective processes of the combination therapy may proceed by upregulating Tregs, preventing BBB disruption and subsequently decreasing downstream effects such as edema and hemorrhage transformation. On the other hand, after the rt-PA thrombolysis, the immune inflammatory response would be aggravated because of the intrusion of cerebrospinal fluid into the circulation through the impaired BBB. Previous studies have demonstrated that Tregs are the key cerebroprotective immunomodulators in acute stroke. Referring to the results of this study, we speculate that the anti-inflammatory effect of the combination therapy works by upregulating the Tregs and then promoting the production of anti-inflammatory factors.

There are some limitations of this study. We have conducted a parallel observation of the A. membranaceus and ligustrazine combination therapy in providing neuroprotection, anti-inflammation, and Tregs regulation effects. However, we have not found whether regulating Tregs and its related cytokines is the upstream mechanism of the combination therapy and may protect neurological function and inhibit inflammatory reaction. Further studies with corresponding objective must be performed. Furthermore, we only performed the experiment on 24 h after R/I treatment. The follow-up effects of the combination therapy are still unclear. With that in mind, studies focusing on the long-term effects of the combination therapy also need to be promoted.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval and consent to participate
The scheme was authorized by Ethics Committee of the 2nd affiliated Hospital, Guangzhou University of Chinese Medicine.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study is supported by the National Natural Science Foundation of China (No. 81804038 to R.P. and No. 81873262 to Y.H.), China Postdoctoral Science Foundation (No. A2-BBK429152K07 to R.P.), the Natural Science Foundation of Guangdong Province (No. 2014A030310457 to R.P.), the Project of Science and Technology Bureau of Guangdong Province (No. 2016A020226030 to R.P.), and the Special Research Foundation of Science and Technology for Traditional Chinese Medicine from Guangdong Hospital of Chinese Medicine (No. YN2016QJ17 to R.P.).

ORCID iD
Hongxia Chen https://orcid.org/0000-0001-5010-7867

References
1. Adams H, Adams R, Del Zoppo G, et al. (2005) Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the stroke council of the American
heart association/American stroke association. *Stroke* 36(4): 916–923.

2. Lees KR, Bluhmki E, von Kummer R, et al. (2010) Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. *Lancet (London, England)* 375(9727): 1695–1703.

3. Saver JL, Kidwell C, Eckstein M, et al. (2004) Prehospital neuroprotective therapy for acute stroke: results of the field administration of stroke therapy-magnesium (FAST-MAG) pilot trial. *Stroke* 35(5): 106–108.

4. Ormstad H, Verkerk R, Aass HCD, et al. (2013) Inflammation-induced catabolism of tryptophan and tyrosine in acute ischemic stroke. *Journal of Molecular Neuroscience* 51(3): 893–902.

5. Dziedzic T (2015) Systemic inflammation as a therapeutic target in acute ischemic stroke. *Expert Review of Neurotherapeutics* 15(5): 523–531.

6. Ito Y, Ohkubo T, Asano Y, et al. (2010) Nitric oxide production during cerebral ischemia and reperfusion in eNOS- and nNOS-knockout mice. *Current Neuровascular Research* 7(1): 23–31.

7. Li P, Gan Y, Sun BL, et al. (2013) Adoptive regulatory T-cell therapy protects against cerebral ischemia. *Annals of Neurology* 74(3): 458–471.

8. Pan RH and Huang Y (2012) The application of Qi benefiting and blood activating method in thrombolytic therapy of acute cerebral infarction. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 32(8): 1126–1129.

9. Yan L and Huang DB (2012) Effects of astragaloside on neurotransmitters and expression of c-fos mRNA in hippocampus after ischemic brain injury in rats. *Chinese Journal of Pathophysiology* 28(2): 263–268.

10. Ding Y, Hou X, Chen L, et al. (2013) Protective action of tetramethylpyrazine on the medulla oblongata in rats with chronic hypoxia. *Autonomic Neuroscience* 173(1–2): 45–52.

11. Chen HJ, Shen YC, Shiao YJ, et al. (2015) Multiplex brain proteomic analysis revealed the molecular therapeutic effects of Buyang Huanwu decoction on cerebral ischemic stroke mice. *PLoS ONE* 10(10): e0140823.

12. Cai J, Pan R, Jia X, et al. (2014) Astragalus membranaceus and ligustrazine combination ameliorates micro-haemorrhage by maintaining blood–brain barrier integrity in cerebrally ischaemic rats. *Journal of Ethnopharmacology* 158: 301–309.

13. Overgaard K, Sereghy T, Boysen G, et al. (1992) A rat model of reproducible cerebral infarction using thrombotic blood clot emboli. *Journal of the International Society of Cerebral Blood Flow & Metabolism* 12(3): 484–490.

14. Zhang RL, Chopp M, Zhang ZG, et al. (1997) A rat model of focal embolic cerebral ischemia. *Brain Research* 766(1–2): 83–92.

15. Bederson JB, Pitts LH, Tsuji M, et al. (1986) Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. *Stroke* 17(3): 472–476.

16. Yang G, Chan PH, Chen J, et al. (1994) Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia. *Stroke* 25(1): 165–170.

17. Brea D, Agulla J, Rodriguez-Yanez M, et al. (2014) Regulatory T cells modulate inflammation and reduce infarct volume in experimental brain ischaemia. *Journal of Cellular and Molecular Medicine* 18: 1571–1579.

18. Mao L, Li P, Zhu W, et al. (2017) Regulatory T cells ameliorate tissue plasminogen-activator-induced brain haemorrhage after stroke. *Brain: A Journal of Neurology* 140(7): 1914–1931.

19. Li H, Wang P, Huang F, et al. (2017) Astragaloside IV protects blood-brain barrier integrity from LPS-induced disruption, via, activating Nrf2 antioxidant signaling pathway in mice. *Toxicology and Applied Pharmacology* 340: 58–66.

20. Tan F, Fu W, Cheng N, et al. (2015) Ligustrazine reduces blood-brain barrier permeability in a rat model of focal cerebral ischemia and reperfusion. *Experimental and Therapeutic Medicine* 9(5): 1757–1762.

21. Varatharaj A and Galea I (2016) The blood-brain barrier in systemic inflammation. *Brain Behavior and Immunity* 60: 1–12.

22. Li X, Qu L, Dong Y, et al. (2014) A review of recent research progress on the astragalus genus. *Molecules* 19(11): 18850–18880.

23. Zou J, Gao P, Hao X, et al. (2018) Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives. *European Journal of Medicinal Chemistry* 147: 150–162.

24. Pan R, Cai J, Zhan L, et al. (2017) Buyang Huanwu decoction facilitates neurorehabilitation through an improvement of synaptic plasticity in cerebral ischemic rats. *BMC Complementary and Alternative Medicine* 17(1): 173.

25. Liesz A, Suri-Payer EC, Veltkamp C, et al. (2009) Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. *Nature Medicine* 15(2): 192–199.

26. Mizuma A and Yenari MA (2017) Anti-inflammatory targets for the treatment of reperfusion injury in stroke. *Frontiers in Neurology* 8: 467.